OncoSec Medical (ONCS) Faces Nasdaq Delisting
- June 23rd, 2023
- 311 views
On June 15, 2023, the Chapter 7 bankruptcy trustee for OncoSec Medical Incorporated (Nasdaq: ONCS) received a letter from Nasdaq's Listing Qualifications Department, as disclosed in a regulatory filing with the SEC.
The letter informed both the trustee and the company that Nasdaq has decided to delist OncoSec's securities based on several factors, including the Chapter 7 filing, concerns regarding existing securities holders' equity interest, and non-compliance with listing requirements. It further stated that the trading of the company's common stock will be suspended on June 26, 2023, and the securities will be removed from listing and registration on Nasdaq.
OncoSec Medical Incorporated stated that it does not intend to challenge the determination made by Nasdaq's Listing Qualifications Department. As a result, the company expects that its common stock will be suspended from trading at the start of business on June 26, 2023, and subsequently delisted from Nasdaq.
Despite the impending delisting, $ONCS is currently experiencing pre-market trading at $0.43, representing an increase of $0.22 (+104.57%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login